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Abstract
Background: Ovarian borderline tumors (OBTs) are frequently diagnosed in women of reproductive age. There is
no consensus about their management, and it sometimes represents a dilemma about what should be done: fertility-
sparing surgery or a hysterectomy with salpingo-oophorectomy? Case: A 32-year-old nulligravida, diagnosed with
a right ovarian borderline tumor is presented. She underwent pelvic washings, right salpingo-oophorectomy,
appendectomy, and omental and peritoneal biopsies (laparotomic approach). Macroscopically, the left ovary was
normal and subsequent exploration for staging was also normal, including the lymph nodes. Intraoperatively,
frozen section examination was unclear, suggesting an OBT. Results: The final histopathologic diagnosis was
ovarian borderline tumor, stage IIC (International Federation of Gynecology and Obstetrics [FIGO] staging). The
patient expressed a desire to preserve her fertility. Thirty-six months postsurgery, she became pregnant sponta-
neously and delivered a healthy newborn at term. Conclusions: Conservative surgery can be performed in young
patients treated for an OBT, provided they are closely followed up and that this surgery is performed after careful
consideration and informed consent. It is, however, controversial with respect to performing hysterectomy and
salpingo-oopherectomy upon the patient’s completion of childbearing. ( J GYNECOL SURG 29:292)
Introduction
Ovarian borderline tumors (OBTs) are frequently di-agnosed in women of reproductive age. There is no
consensus regarding their management, and it sometimes
represents a dilemma: fertility-sparing surgery or a hysterec-
tomy with salpingo-oophorectomy?
Case
A healthy, 32-year-old nulligravida required a gynecologic
assessment for amenorrhea. She was diagnosed with a pelvic
retro-uterine mass, 112· 106mm, with an apparent right
adnexal origin. The patient’s CA-125 levels were elevated
(324U/mL) and diagnostic laparoscopy confirmed an ad-
nexal tumor with a suspicious ultrasound and macroscopic
appearance. The patient was subjected to pelvic washings,
right salpingo-oophorectomy, appendectomy, and omental
and peritoneal biopsies. Macroscopically, the left ovary ap-
peared normal upon exploration for staging, and the lymph
nodes were normal in size. The results of the intraoperative
frozen section analysis were unclear, but suggested an OBT.
The final histopathologic diagnosis was serous borderline
ovarian tumor with foci of microinvasion and the presence of
malignant cells in pelvic washings, and peritoneal invasive
implants at the pouch of Douglas (stage IIC, International
Federation of Gynecology and Obstetrics [FIGO]).
Results
The patient expressed a desire to preserve her fertility.
Based on a multidisciplinary decision, she was subjected to
six cycles of chemotherapy and a close follow-up, in which
she was asymptomatic and without any signs of recurrence.
Thirty-six months postsurgery, she became pregnant
spontaneously. She had an uneventful pregnancy and a eu-
tocic delivery at term. Fifty months later, she was clinically
well, and not planning further pregnancies. A decision was
then made to perform a hysterectomy and a contralateral
salpingo-oopherectomy.
Discussion
OBTs are a heterogeneous group of tumors, representing
15% of all epithelial ovarian tumors.1 They tend to be diag-
nosed early compared with other malignant tumors, and
frequently affect women in reproductive age. Preoperatively,
borderline tumors are often presumed to be either benign or
malignant ovarian masses; OBTs and stage I epithelial
ovarian carcinoma (EOC) may have a similar ultrasono-
graphic patterns.2 CA-125 is often measured as a second
stage test to estimate the likelihood of malignancy in adnexal
lesions detected by ultrasound examination: median serum
CA-125 levels are higher in patients with OBT than in heal-
thy controls, and lower than in those with invasive ovarian
Department of Gynaecology/Obstetrics, Hospital D. Estefaˆnia, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.
JOURNAL OF GYNECOLOGIC SURGERY
Volume 29, Number 6, 2013
ª Mary Ann Liebert, Inc.
DOI: 10.1089/gyn.2013.0065
292
cancers.3 According Zacharakis et al.,4 preoperative values of
CA-125 > 100 international units (IU)/mL proved to be an
independent discriminator between OBTs and stage I EOC:
women with CA-125> 100 IU/mL had an almost three times
greater likelihood of belonging in the EOC group. Mis-
interpreting OBT as invasive ovarian cancer may result in
serious and unnecessary procedures and morbidity (such as
hysterectomy and lymphadenectomy).
In this case, because the tumor appeared suspicious upon
macroscopic examination, a right salpingo-oophorectomy
with intraoperative histopathologic examination was per-
formed, which suggested an OBT. Previous studies show
that these tumors can be correctly diagnosed in 58%–86% of
cases by intraoperative frozen section analysis, depending
upon the experience of the pathologist.1
As the patient was nulligravid and the tumor was at an early
stage (as in the majority of reported cases), fertility-preserving
surgery was performed. Final diagnosis confirmed a stage IIC
(FIGO) serous OBT. The patient decided against undergoing a
hysterectomy and a contralateral salpingo-oopherectomy, de-
spite being informed of the associated risks. Conservative sur-
gery can be performed in younger patients treated for OBTs,
provided that they are carefully followed-up.1,5,6 The overall
risk of recurrence after conservative surgery ranges from 7% to
30%.7 The postoperative management protocol is far from clear:
most clinicians agree that there are no advantages to chemo-
therapy for stage I tumors. However, with respect to stage
II–IV tumors, there is no consensus on the benefits of chemo-
therapy and such benefits have never been proven.1 Many in-
vestigators believe that factors that may bring about a poorer
prognosis are the presence of invasive peritoneal implants,1,5 an
older age at diagnosis, elevated preoperative CA-125 levels,
micropapillary histology,5 and foci of microinvasion.8 Accord-
ing to a study by Gershenson et al.,9 serous OBTs with peri-
toneal implants have a relapse rate of 31%–45%, with a median
time from diagnosis to recurrence of 24 months. In cases with a
higher risk of persistence/recurrence, patients should be given
postoperative chemotherapy, and followed closely thereafter.5
Given the high risk factors and poor prognosis of this
patient, she received adjuvant therapy. She became sponta-
neously pregnant after trying to conceive for <1 year. Pre-
vious studies have shown that pregnancy itself does not
affect the prognosis of the disease.10,11 A review identified
254 pregnancies in 206 patients; the investigators calculated
the overall pregnancy rate at 48%, based on the published
numbers of women trying to conceive.12 Another study re-
ported 60%–88% of spontaneous pregnancy rates following
fertility saving surgery, therefore not justifying overtreat-
ment for fertility.13
Fifty months postsurgery, the patient was clinically well
and not planning further pregnancies; therefore, she decided
to undergo a hysterectomy and a contralateral salpingo-
oopherectomy. This is a controversial topic, and the guide-
lines from the National Comprehensive Cancer Network
(NCCN) argue about this approach (category 2B).14
Conclusions
Combining tumor marker measurement and ultrasonog-
raphy might increase the accuracy of diagnosis, in order to
choose the hospital (with experienced gynecologic patholo-
gists) and determine which type of surgery is appropriate.
In conclusion, a fertility-sparing approach in special cases
should be decided only after thorough discussion and in-
formed consent by the patient, and by carefully balancing the
risks and benefits. Gynecologic oncologists should be fully
aware of their double role in treating the malignant disease
as well as in providing oncofertility care to young patients.
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